Sign in
Not yet taking people in BangladeshPhase 2/3

Low-dose emicizumab versus low-dose clotting factor to prevent bleeding in hemophilia A

Compares low doses of emicizumab and clotting factor in hemophilia A.

Key facts

Who runs it
Dhaka Medical College
Where
Dhaka, BangladeshSee the site
Trial code
Registry title
Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
20 people, planned
Started
1 Jun 2025
Planned end
31 Jul 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Emicizumab Injection
  • Factor VIII (FVIII)
Record updated
22 April 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with severe hemophilia A, with or without inhibitors to factor VIII. It compares low dose Emicizumab with low dose Factor VIII.

Sex
Men and women can join.
Disease stage
Severe hemophilia A, with or without an inhibitor to factor VIII.

Main reasons for not taking part

  • People with severe hemophilia A who are not willing to take part cannot join.

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Severe hemophilia A patient with or without inhibitor to factor VIII

Who cannot take part

  • 1. Severe hemophilia A patient not willing to participate

Where in Bangladesh

  • Dhaka Medical College HospitalDhaka, BangladeshContact: Akhil R. Biswas, MBBS,FCPSNot yet recruiting

About the trial

What the trial wants to find out

Low dose factor VIII prophylaxis is practiced around the world. Role of standard dose Emicizumab prophylaxis is well established. Emicizumab is an expensive drug. Standard dose Emicizumab prophylaxis is very expensive for hemophilia A patients and troublesome for government to ensure continuous supply. This study intends to compare low dose Factor VIII prophylaxis with low dose Emicizumab prophylaxis and compare whether low dose Emicizumab is as effective as low dose Factor VIII prophylaxis. So, it is possible to continue prophylaxis program in hemophilia A patients with a cost-effective way in our country without risking the patient health. Moreover, Emicizumab prophylaxis reduces the chance of developing inhibitor to Factor VIII and it is convenient for administration due to less frequent and subcutaneous administration. 20 severe hemophilia A patients will be selected randomly from interested patients for this study. 6 patients with inhibitor will be randomized in Low dose Emicizumab with Inhibitor group (I) and rest 14 will be randomized by block randomization in Low dose Emicizumab (without inhibitor-WI) and low dose Factor VIII group at 4:10 ratio. Initial loading dose will be given and the participants will be followed up for 6 months. At the end of the study Annualized bleeding rate (ABR), Annualized joint bleeding rate (AJBR), Annualized spontaneous bleeding rate (ASBR), APTT will be compared among the groups. Inhibitor to factor VIII will also be evaluated after six months in Factor VIII group.

The 3 groups in the trial

  • Emicizumab Group- ITreatment being tested

    Severe hemophilia A patients with inhibitor

    Treatment: Emicizumab Injection

  • Emicizumab Group- WITreatment being tested

    Severe hemophilia A Patients without inhibitor (Emicizumab Group):

    Treatment: Emicizumab Injection

  • Factor VIII GroupExisting treatment, for comparison

    Severe hemophilia A Patients without inhibitor.

    Treatment: Factor VIII (FVIII)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison of Low Dose Emicizumab and Low Dose Factor VIII as a Prophylaxis in Hemophilia A Patients- a Randomized Control Trial'
Plain-language title
Low-dose emicizumab versus low-dose clotting factor to prevent bleeding in hemophilia AGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 April 2025